Get the Stockscreener App
46.88
1.55%
-0.74
Pre-market:
46.98
0.10
+0.21%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $46.88, with a volume of 22.41M.
It is down -1.55% in the last 24 hours and down -11.66% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$47.62
Open:
$47
24h Volume:
22.41M
Relative Volume:
1.65
Market Cap:
$100.96B
Revenue:
$47.64B
Net Income/Loss:
$5.42B
P/E Ratio:
17.56
EPS:
2.67
Net Cash Flow:
$13.09B
1W Performance:
-5.50%
1M Performance:
-11.66%
6M Performance:
-13.41%
1Y Performance:
+7.35%
1-Day Range:
$46.52
$47.40
1-Week Range:
$46.52
$50.65
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.88 | 100.96B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com
Bristol Myers Squibb Co. Becomes Oversold - Nasdaq
Bristol Myers Squibb Co. Named Top Dividend Stock With Insider Buying and 5.21% Yield (BMY) - Nasdaq
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com
Improving Access to Care by Strengthening Local Health System Capacity - CSRwire
The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle - Yahoo Finance
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - BioSpace
Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific - MSN
Bristol Myers Squibb to Invest $40B in the U.S. - Contract Pharma
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
Bristol Myers Squibb appoints new general counsel - | Governance Intelligence
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnology News
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Benzinga
Bristol-Myers GC Hands Over Legal Department To Successor - Law360
Bristol Myers Squibb names new executive vice president By Investing.com - Investing.com Canada
Bristol Myers (BMY) Experiences Increased Bearish Activity in Op - GuruFocus
Bristol Myers (BMY) Experiences Increased Bearish Activity in Options Market | BMY Stock News - GuruFocus
Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over Five Years | BMY Stock News - GuruFocus
Bristol Myers Squibb Appoints Cari Gallman as EVP, General Counsel and Chief Policy Officer - citybiz
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers (BMY) Appoints Cari Gallman as New General Counsel - GuruFocus
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours - PMLiVE
Bristol Myers Squibb announces $40bn US investment plan over five years - Yahoo Finance
Bristol Myers Squibb names new executive vice president - Investing.com
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Quantisnow
Bristol Myers to invest $40 billion in the US over 5 years | Business Information & News | FE - Westlaw Today
Bristol Myers to invest $40 billion in the US over 5 years - Reuters
Bristol Myers to invest $51.6 billion in the US over 5 years - The Straits Times
Company with deep NJ roots plans hundreds of more layoffs out of New Jersey - New Jersey 101.5
Bristol Myers to invest $40 billion in the US over 5 years, CEO says - marketscreener.com
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb Laying Off 500+ Employees From Lawrence Township Office - dailyvoice.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey
Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus
Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey
MHRA approval for BMS’ SC Opdivo - The Pharma Letter
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance
BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus
Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus
Bristol Myers Squibb: innovating oncology care - MSN
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey
BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Our impact - Bristol Myers Squibb
Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance
HSBC Adjusts Price Target for Bristol Myers (BMY) Amid Tariff Co - GuruFocus
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):